Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GU-228: MMF and Prednisone for Immune-Related Hepatitis
NCT07663422Phase 2Recruiting
- Sponsor
- Fox Chase Cancer Center
- Start
- Jul 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mycophenolate mofetil in immune-mediated hepatitis (IMH), sponsored by Fox Chase Cancer Center. Primary endpoint: Response rate of immunotherapy-related hepatitis to MMF and prednisone at 30 days. Started Jul 2026; status: recruiting.
02
Drugs
mycophenolate mofetil
03
Conditions
immune-mediated hepatitis (IMH)
Beyond the preview
Go deeper on NCT07663422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07663422.